Company Projected Revenue: Protagenic Therapeutics (PTIX)
The development of Protagenic Therapeutics (PTIX) relies on the validation of TCAP peptides for the treatment of anxiety. The company's projected sales levels reflect expectation dynamics, where the 0.00 mark captures this metric. Revenues are based on insurance company payouts for PTSD treatment; however, the high binary vulnerability of the pipeline creates significant risks due to the dependence on a single drug.
Financial and market metric breakdowns for Protagenic Therapeutics, Inc. (PTIX)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Protagenic Therapeutics|PTIX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Protagenic Therapeutics|PTIX - Company Cumulative Indebtedness|Debts to Book Capitalization Protagenic Therapeutics|PTIX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Protagenic Therapeutics|Quick Liquidity protagenic.com
- earnings and market ratios statistics:
PTIX - Final Profit|Projected Future Earnings Protagenic Therapeutics|PTIX - P/E Multiple|Future Price to Earnings protagenic.com|PTIX - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Protagenic Therapeutics Inc.|PTIX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Protagenic Therapeutics|PTIX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months protagenic.com|PTIX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Protagenic Therapeutics
- revenue and sales proceeds data:
Summary company analysis:Protagenic Therapeutics
Future sales volume estimates the potential cash flow from the sale of products and services across all business units. The calculation model determines the company's fundamental stability through projected revenue. By analyzing the projected sales trajectory, an investor identifies capital consolidation phases. For Protagenic Therapeutics (PTIX), this indicator is critical due to the binary risk associated with a single peptide candidate. Current price action reflects the model's survival dependence on the outcome of early clinical trials.
Direct competitors
Company Future Sales Volume BIIB (Biogen)|NBIX (Neurocrine Biosciences, Inc.) - Company Future Revenue|Company Projected Revenue Regencell RGC|Company Projected Revenue Volume AXSM (Axsome Therapeutics Inc)|ACADIA Pharmaceuticals - Projected Sales Volume|XENE - Projected Sales Volume|VKTX: Projected Sales Volume|Company Expected Revenue SUPN (Supernus)|CPRX (Catalyst Pharmaceuticals Inc) - Projected Sales Volume|DNLI: Company Future Revenue|Company Projected Revenue harmonybiosciences.com (HRMY)|Biohaven - Company Revenue Forecast|Projected Sales Volume AMLX (amylyx.com)|Trevi Pharma (TRVI) - Company Expected Sales Volume|Praxis Corp - Projected Sales Volume|Anavex Corp (AVXL) - Company Future Sales Volume|CBLL: Projected Sales Volume|Prothena Biosciences - Company Future Revenue|ALEC (alector.com) - Projected Sales Volume|Company Revenue Forecast ANNX (Annexon Biosciences)|Company Projected Revenue Omeros Corporation (OMER)|Neurogene Corp - Company Revenue Forecast|Company Projected Revenue AC Immune S.A. ACIU|Company Future Sales Voyager Therapeutics (VYGR)|Neumora - Projected Sales Volume|Company Expected Revenue SCLX|Tevogen Bio Inc. (TVGN) - Company Projected Revenue|Company Revenue Forecast ACOG|CGTX (cogrx.com) - Projected Sales Volume|Company Future Sales Volume inhibikase.com (IKT)|Company Projected Revenue Cassava Sciences Inc (SAVA)|Company Future Sales Assertio|Projected Sales Volume COYA (Coya Therapeutics, Inc.)|Company Projected Revenue Volume VTGN (VistaGen Therapeutics Inc)|OVID: Company Future Sales Volume|ABOS: Company Projected Revenue|CervoMed (CRVO) - Company Projected Revenue|Company Expected Sales Volume Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Projected Sales Volume|Company Revenue Forecast PEPG (PepGen)|Company Future Sales Volume JUNS (Jupiter Neurosciences, Inc.)|Projected Sales Volume relmada.com (RLMD)|Company Projected Revenue Annovis Bio Corp ANVS|GRCE: Company Revenue Forecast|AIFF - Company Projected Revenue|KLTO (anewmeds.com) - Company Revenue Forecast|NRSN (NeuroSense Therapeutics Ltd.) - Company Future Sales Volume|revivapharma.com - Company Future Revenue|MTVA (metaviatx.com) - Projected Sales Volume|NRXS: Company Future Revenue|Projected Sales Volume HSDT|PASG - Company Expected Sales Volume|Projected Sales Volume NEUP (Neuphoria Therapeutics)|NERV: Company Revenue Forecast|ATHA: Company Future Sales Volume|Addex Therapeutics Ltd - Company Projected Revenue Volume|Alzamend Neuro, Inc. (ALZN) - Company Projected Revenue|CYCN (Cyclerion Therapeutics Inc.) - Company Projected Revenue|KTTA (pasitheaclinics.com) - Projected Sales Volume|Company Future Sales Volume Cortigent (CRGT)|Projected Sales Volume ATXI|BCLI - Company Expected Sales Volume|Projected Sales Volume CARA (Cara Therapeutics, Inc)|Chromocell Therapeutics Corporation (CHRO) - Company Expected Sales Volume|ELYM - Company Projected Revenue|Company Sales Forecast intracellulartherapies.com (ITCI)|Longboard (LBPH) - Company Projected Revenue|Marinus Pharmaceuticals Inc - Company Future Revenue|Company Future Sales Volume NKGN|NeuroBo - Company Expected Revenue|Company Projected Revenue Sage Therapeutics, Inc (SAGE)|Company Future Sales Volume Synaptogenix SNPX|Trevena, Inc. - Company Future Sales Volume|VIGL: Company Revenue Forecast|WENA: Company Future Sales Volume|Company Expected Sales Volume Cerevel Therapeutics
